Week 16: Prevalence and management of anaemia by fibrosis stage
| Characteristic | Bridging fibrosis (F3)* (N=752) | Cirrhosis (F4) (N=835) | Overall (N=1587) |
|---|---|---|---|
| Grade 1–4 anaemia† (all cause)—no. (%) | 413 (55) | 518 (62) | 931 (59) |
| Grade 3 anaemia† (all cause)—no. (%) | 189 (25) | 238 (29) | 427 (27) |
| Grade 4 anaemia† (all cause)—no. (%) | 26 (3) | 35 (4) | 61 (4) |
| d/c TVR due to anaemia†—no. (%) | 14 (2) | 31 (4) | 45 (3) |
| Initial RBV dose (mg/day)—mean | 1106 | 1120 | 1114 |
| Initial RBV dose (mg/kg/day)—mean | 14.6 | 14.3 | 14.4 |
| RBV dose reductions—no. (%) | 270 (36) | 356 (43) | 630 (40) |
| EPO use—no. (%) | 138 (19) | 194 (23) | 332 (21) |
| Blood transfusion—no. (%) | 60 (8) | 96 (12) | 157 (10) |
| RBV dose reduction+other intervention (EPO or blood transfusion)—no. (%) | 126 (17) | 182 (22) | 309 (20) |
*Includes three F1 patients and three F2 patients.
†Included in this category are all related events that were described with a variety of descriptive terms.
d/c, discontinued; EPO, erythropoietin; RBV, ribavirin; TVR, telaprevir.